FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100064774> ?p ?o ?g. }

• W2100064774 endingPage "139" @default.
• W2100064774 startingPage "131" @default.
• W2100064774 abstract "Hyperlipidaemia is a pivotal risk factor for the development of atherosclerotic disease. A large number of studies have demonstrated that the treatment of abnormalities in lipoprotein levels reduces the risk for myocardial infarction, peripheral vascular disease, carotid artery disease, stroke, and cardiovascular mortality. Despite the development of multiple drug classes to treat dyslipidaemias and the promulgation of clearly defined guidelines for the management of lipid disorders, dyslipidaemia tends to be undertreated in the majority of patients at risk for cardiovascular disease. A part of the reluctance to treat different lipoprotein fractions to goal levels is attributable to physician- and patient-related concerns over the increasing toxicity of available therapies, as their dosages are increased. The risks of hepatotoxicity, myalgia, and rhabdomyolysis are fairly well characterised in patients receiving statins, fibrates and niacin. Another issue affecting treatment success rates is the fact that many patients with complex dyslipidaemias are inadequately responsive to single-agent therapy. As the epidemics of obesity, metabolic syndrome and diabetes mellitus continue to worsen, physicians will encounter severe, mixed dyslipidaemias more frequently. Many of these patients will require combinations of drugs to address the various metabolic derangements causing changes in multiple lipoprotein fractions. Although the need for combination therapy is well-established in the management of disorders, such as hypertension and diabetes, it is less often used for the treatment of dyslipidaemias. The development of safe, cost-effective, and efficacious combination dyslipidaemic therapy is an important goal in cardiovascular medicine. Simvastatin plus ezetimibe has recently been combined as a fixed dose therapy, which offers clinicians the opportunity to simultaneously inhibit two key pathways in cholesterol metabolism: hepatic cholesterol biosynthesis and the absorption of cholesterol at the level of the proximal jejunum. This dual mechanism of inhibition substantially increases the capacity to decrease serum levels of atherogenic low-density lipoproteins and increase high-density lipoprotein, compared with that observed when either drug is used alone. This combination increases the likelihood of therapeutic success in patients with dyslipidaemia." @default.
• W2100064774 created "2016-06-24" @default.
• W2100064774 creator A5054876477 @default.
• W2100064774 creator A5055380940 @default.
• W2100064774 date "2005-01-01" @default.
• W2100064774 modified "2023-09-26" @default.
• W2100064774 title "Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia" @default.
• W2100064774 cites W1965296791 @default.
• W2100064774 cites W1968607982 @default.
• W2100064774 cites W1971163980 @default.
• W2100064774 cites W1971797638 @default.
• W2100064774 cites W1981798840 @default.
• W2100064774 cites W1987251032 @default.
• W2100064774 cites W1995116750 @default.
• W2100064774 cites W1995171938 @default.
• W2100064774 cites W1998336053 @default.
• W2100064774 cites W1998387424 @default.
• W2100064774 cites W1999226510 @default.
• W2100064774 cites W2013961975 @default.
• W2100064774 cites W2022842079 @default.
• W2100064774 cites W2022996249 @default.
• W2100064774 cites W2031606478 @default.
• W2100064774 cites W2036151218 @default.
• W2100064774 cites W2041696629 @default.
• W2100064774 cites W2047410519 @default.
• W2100064774 cites W2050466097 @default.
• W2100064774 cites W2053536280 @default.
• W2100064774 cites W2058218400 @default.
• W2100064774 cites W2063908227 @default.
• W2100064774 cites W2066342412 @default.
• W2100064774 cites W2067055784 @default.
• W2100064774 cites W2078332901 @default.
• W2100064774 cites W2090984426 @default.
• W2100064774 cites W2103042683 @default.
• W2100064774 cites W2106343349 @default.
• W2100064774 cites W2109063792 @default.
• W2100064774 cites W2111385165 @default.
• W2100064774 cites W2111525459 @default.
• W2100064774 cites W2117592927 @default.
• W2100064774 cites W2123936150 @default.
• W2100064774 cites W2125589683 @default.
• W2100064774 cites W2127626139 @default.
• W2100064774 cites W2127719007 @default.
• W2100064774 cites W2134068835 @default.
• W2100064774 cites W2140072878 @default.
• W2100064774 cites W2150797190 @default.
• W2100064774 cites W2153768583 @default.
• W2100064774 cites W2154095174 @default.
• W2100064774 cites W2154704322 @default.
• W2100064774 cites W2155693224 @default.
• W2100064774 cites W2157664837 @default.
• W2100064774 cites W2163252871 @default.
• W2100064774 cites W2168876694 @default.
• W2100064774 cites W2169523655 @default.
• W2100064774 cites W2326764800 @default.
• W2100064774 cites W2389739907 @default.
• W2100064774 cites W2951646900 @default.
• W2100064774 cites W4238251256 @default.
• W2100064774 cites W424467158 @default.
• W2100064774 doi "https://doi.org/10.1517/14656566.6.1.131" @default.
• W2100064774 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15709890" @default.
• W2100064774 hasPublicationYear "2005" @default.
• W2100064774 type Work @default.
• W2100064774 sameAs 2100064774 @default.
• W2100064774 citedByCount "31" @default.
• W2100064774 countsByYear W21000647742012 @default.
• W2100064774 countsByYear W21000647742013 @default.
• W2100064774 countsByYear W21000647742014 @default.
• W2100064774 countsByYear W21000647742016 @default.
• W2100064774 countsByYear W21000647742018 @default.
• W2100064774 countsByYear W21000647742020 @default.
• W2100064774 countsByYear W21000647742021 @default.
• W2100064774 countsByYear W21000647742023 @default.
• W2100064774 crossrefType "journal-article" @default.
• W2100064774 hasAuthorship W2100064774A5054876477 @default.
• W2100064774 hasAuthorship W2100064774A5055380940 @default.
• W2100064774 hasConcept C126322002 @default.
• W2100064774 hasConcept C134018914 @default.
• W2100064774 hasConcept C177713679 @default.
• W2100064774 hasConcept C2776329913 @default.
• W2100064774 hasConcept C2776839432 @default.
• W2100064774 hasConcept C2776999253 @default.
• W2100064774 hasConcept C2777482532 @default.
• W2100064774 hasConcept C2778616394 @default.
• W2100064774 hasConcept C2778657065 @default.
• W2100064774 hasConcept C2779134260 @default.
• W2100064774 hasConcept C2780092750 @default.
• W2100064774 hasConcept C2780578515 @default.
• W2100064774 hasConcept C500558357 @default.
• W2100064774 hasConcept C555293320 @default.
• W2100064774 hasConcept C71924100 @default.
• W2100064774 hasConceptScore W2100064774C126322002 @default.
• W2100064774 hasConceptScore W2100064774C134018914 @default.
• W2100064774 hasConceptScore W2100064774C177713679 @default.
• W2100064774 hasConceptScore W2100064774C2776329913 @default.
• W2100064774 hasConceptScore W2100064774C2776839432 @default.
• W2100064774 hasConceptScore W2100064774C2776999253 @default.
• W2100064774 hasConceptScore W2100064774C2777482532 @default.

• next